Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Overview
Explore Arrowhead Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
10.3B
P/E Ratio
51.20
EPS (TTM)
$1.60
ROE
0.36%
ARWR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Arrowhead Pharmaceuticals, Inc. (ARWR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 69.27, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $61.89.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 51.20 and a market capitalization of 10.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.